Showing results (141-150 of 204) with videos related to
Sort By:
Pageof 21
Headache|January 4, 2012
Headache following intracranial neuroendovascular proceduresEric P Baron, Shaye I Moskowitz, Stewart J Tepper, et al.Headache|April 5, 2011
MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraineSheena K Aurora, Stephen D Silberstein, Shashidhar H Kori, et al.Headache|May 6, 2015
AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacksStewart J Tepper, Roger K Cady, Stephen Silberstein, et al.Headache|November 24, 2011
Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodyniaStewart J Tepper, Shashidhar H Kori, Scott W Borland, et al.Headache|December 4, 2019
The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of FindingsStewart J Tepper, Stephen D Silberstein, Noah L Rosen, et al.Cephalalgia : an International Journal of Headache|October 13, 2017
Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraineEgilius Lh Spierings, Jan Lewis Brandes, David B Kudrow, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 12, 2019
Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxietyAndrew M Blumenfeld, Stewart J Tepper, Lawrence D Robbins, et al.Headache|July 8, 2020
Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine AttacksStewart J Tepper, Raghavendra Vasudeva, John H Krege, et al.Postgraduate Medicine|June 10, 2025
Efficacy and safety of rimegepant 75 mg for acute treatment of migraine: a pooled analysis of four randomized, placebo-controlled trialsStewart J Tepper, Jelena M Pavlovic, Shengyuan Yu, et al.Mayo Clinic Proceedings|October 4, 2011
MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatmentsStewart J Tepper, Shashidhar H Kori, Peter J Goadsby, et al.Pageof 21